Confronto
Buserelin vs. Cerebrolysin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
57982-77-1
96889-70-6
Peso molecolare
1239.42 g/mol
nessun dato
Emivita
nessun dato
nessun dato
Sequenza
nessun dato
nessun dato
Meccanismo d'azione
Buserelin
Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
0
4
di cui sull'uomo
0
4
Effetti registrati
2
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Buserelin and Cerebrolysin?
- Buserelin is classified as "Ricerca (altro)", while Cerebrolysin is classified as "Ricerca (altro)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Buserelin or Cerebrolysin?
- The highest available evidence level is "RCT sull'uomo" for Buserelin and "RCT sull'uomo" for Cerebrolysin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Buserelin and Cerebrolysin in Germany and the United States?
- Germania: Buserelin — Su prescrizione, Cerebrolysin — Non chiaro. Stati Uniti: Buserelin — Non approvato, Cerebrolysin — Non approvato. These are factual summaries with source and review date on the individual pages.